CJC-1295, Ipamorelin and growth GHRP-2 Peptide Blend Potential
CJC-1295: Studies have suggested that CJC-1295, a synthetically derived peptide, may potentially increase growth hormone synthesis and boost “mean plasma IGF-I concentrations by 1.5- to 3-fold.”[i] Research reports that this growth hormone increase has been observed in some research cases to have a duration of between 6-8 days. The sustained uptick in growth hormone synthesis after the peptide presentation might be possible with a longer half-life.
Ipamorelin: Ipamorelin is a pentapeptide that findings imply may stimulate production of growth hormone (GSH). Investigations purport that it may act similarly to GHRPs and have been suggested to imitate the naturally occurring ghrelin hunger hormone.[ii] The peptide has been studied for its possible anti-aging potential on skin and organs. The selective nature of Ipamorelin and its lack of influence on the release of other hormones, including cortisol, prolactin, and aldosterone, has been the subject of much research.
GHRP-2: GHRP-2 has been speculated [ii] to increase growth hormone levels in experimental settings by activating the endogenous GHRH signal transduction system. Researchers speculate that it may also inhibit Somatostatin’s effects. Research has suggested that unlike with other growth GHRPs, introducing GHRP-2 to test animals at high quantities does not result in the desensitization seen with other substances. The possible properties include keeping the blood’s growth hormone concentration optimal. Scientists have hypothesized that the peptide has the potential to increase food cravings. “GHRP-2, like ghrelin, increases food intake,” researchers speculated. This means the hormone might be used to study ghrelin’s impact on eating habits.[iii]
CJC-1295, Ipamorelin, and GHRP-2 Peptide Blend Research
Studies suggest that when presented together, CJC-1295 & Ipamorelin & GHRP-2 may have a multiplying and boosting impact on growth hormone production. This may improve growth hormone levels by strengthening the growth hormone pulse and boosting the cells’ activity that generates growth hormone (Somatotrophs). Research suggests that, as a whole, it may have the potential to stimulate a sustained and amplified growth hormone secretion.
CJC-1295, Ipamorelin, GHRP-2 Peptide Blend and Muscle
The major emphasis of studies on this blend has been to explore its apparent potential to stimulate cellular proliferation and tissue development, particularly in promoting increased muscle mass.[iv] It was suggested that the presentation of CJC-1295 might demonstrate tissue-specific effects in research using mouse models with a gene ablation of GHRH (termed GHRHKO). The GHRHKO murine mice given CJC-1295 at 24-hour intervals grew and developed normally. The murine models looked to have attained a larger body weight and length than those given a placebo, but they still did not achieve complete growth normalization when the intervals were expanded to 48 and 72 hours. The femur and tibia lengths of the mouse models given the peptide every 24 and 48 hours, but not at 72 hours, seemed to have reached normal proportions, suggesting normal bone formation.
In addition, it was speculated that all peptide-related groups maintained their relative lean mass and subcutaneous fat mass within healthy ranges. The researchers also noticed something noteworthy: CJC-1295 appeared to have increased total pituitary RNA and growth hormone mRNA. This suggests that somatotroph cells, the cells in the pituitary gland thought to be responsible for manufacturing growth hormone, may have increased.
Immunohistochemistry pictures also corroborated this expansion. This research suggests that CJC-1295 presentation at a higher frequency may help GHRHKO murine mice keep their body composition and growth rates regular. However, its potential seems diminished at intervals every 48 or 72 hours.
CJC-1295 & Ipamorelin & GHRP-2 Blend is available for sale at Biotech Peptides.
CJC-1295, Ipamorelin, growth GHRP-2 Peptide Blend and Bone Density
Several degenerative bone conditions have prompted speculative laboratory research into these peptides. The most common hypothesis in this research was that Ipamorelin may increase bone density.[v] It has been posited that it may stimulate osteoblasts’ proliferation, development, and differentiation (bone-forming cells) using growth hormone-mediated pathways. Ipamorelin and a placebo were tested in a group of mouse models. Bone mineral density changes in the murine models were monitored in real-time using dual X-ray absorptiometry (DXA) at the femur and L6 vertebrae locations. After the research period, mid-diaphyseal peripheral quantitative computed tomography (pQCT) scans were used to examine the femurs of the mouse models. Compared to the control group, the peptide seemed to enhance both body weight and the total BMC (bone mineral content) of the tibia and vertebrae as measured by DXA. Researchers noted that there did not seem to be a substantial change in the total BMC after accounting for the increase in body weight. Bone mineral density (BMD, or the ratio of bone mineral content to bone surface area) may have increased in the tibial region. Still, it seems to have stayed stable in the whole body and the vertebral column.
References
[i] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (growth hormone) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683.
[ii] Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.
[iii] Laferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (growth GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005 Feb;90(2):611-4. doi: 10.1210/jc.2004-1719. PMID: 15699539; PMCID: PMC2824650.
[iv] Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (growth hormoneRH) analog, normalizes growth in the growth hormoneRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi: 10.1152/ajpendo.00201.2006. Epub 2006 Jul 5. PMID: 16822960.
[v] Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The growth hormone secretagogues ipamorelin and growth hormone-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-77. doi: 10.1677/joe.0.1650569. PMID: 10828840.